ノバルティスは予想を上回る強度の Q3 業績を上げ,長期成長目標を上げ,ジェネリック製品の競争にもかかわらず大規模な投資を確認しました. Novartis beat expectations with strong Q3 results, raised long-term growth targets, and confirmed major investments despite generic competition.

ノバルティスは,キスカリ,ケシンプタ,プルービクトのような新薬の強力な業績により,予想以上に強い第3四半期利益と売上を報告し,純利益は39億300万ドル,売上は1391億ドルに上昇した. Novartis reported stronger-than-expected third-quarter profits and sales, with net income rising to $3.93 billion and sales reaching $13.91 billion, driven by strong performance from newer drugs like Kisqali, Kesimpta, and Pluvicto. 汎用医薬品の競争により,心臓薬Entrestoの販売が滞ったにもかかわらず,同社は2025年の見通しを再確認し,高単数桁の売上高成長と低ティーン期の営業収益の成長を予測した. Despite flat sales of its heart drug Entresto due to generic competition, the company reaffirmed its 2025 outlook, projecting high-single-digit sales growth and low-teen operating income growth. 2029年度から毎年6%の長期販売成長目標を掲げ,特許期限の償還を取り消すため,米国バイオテクノロジー・アビティの12億ドルの取得を含め,継続的な投資が確認された. It also raised its long-term sales growth target to 6% annually through 2029 and confirmed ongoing investments, including a $12 billion acquisition of U.S. biotech Avidity, to offset patent expirations.